These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 29900496)

  • 1. Zika Virus Envelope Protein and Antibody Complexes.
    Dai L; Wang Q; Song H; Gao GF
    Subcell Biochem; 2018; 88():147-168. PubMed ID: 29900496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal Antibodies against Zika Virus NS1 Protein Confer Protection via Fc
    Yu L; Liu X; Ye X; Su W; Zhang X; Deng W; Luo J; Xiang M; Guo W; Zhang S; Xu W; Yan Q; Wang Q; Cui Y; Wu C; Guo W; Niu X; Zhang F; Lei C; Qu L; Chen L; Feng L
    mBio; 2021 Feb; 12(1):. PubMed ID: 33563822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus.
    Swanstrom JA; Plante JA; Plante KS; Young EF; McGowan E; Gallichotte EN; Widman DG; Heise MT; de Silva AM; Baric RS
    mBio; 2016 Jul; 7(4):. PubMed ID: 27435464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Monoclonal Antibodies Potently Neutralize Zika Virus and Select for Escape Mutations on the Lateral Ridge of the Envelope Protein.
    Bailey MJ; Broecker F; Freyn AW; Choi A; Brown JA; Fedorova N; Simon V; Lim JK; Evans MJ; García-Sastre A; Palese P; Tan GS
    J Virol; 2019 Jul; 93(14):. PubMed ID: 31043537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of differential Zika and dengue virus neutralization by a public antibody lineage targeting the DIII lateral ridge.
    Zhao H; Xu L; Bombardi R; Nargi R; Deng Z; Errico JM; Nelson CA; Dowd KA; Pierson TC; Crowe JE; Diamond MS; Fremont DH
    J Exp Med; 2020 Feb; 217(2):. PubMed ID: 31757867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies.
    Gallichotte EN; Young EF; Baric TJ; Yount BL; Metz SW; Begley MC; de Silva AM; Baric RS
    mBio; 2019 Sep; 10(5):. PubMed ID: 31530669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis of potent Zika-dengue virus antibody cross-neutralization.
    Barba-Spaeth G; Dejnirattisai W; Rouvinski A; Vaney MC; Medits I; Sharma A; Simon-Lorière E; Sakuntabhai A; Cao-Lormeau VM; Haouz A; England P; Stiasny K; Mongkolsapaya J; Heinz FX; Screaton GR; Rey FA
    Nature; 2016 Aug; 536(7614):48-53. PubMed ID: 27338953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant Chimpanzee Adenovirus Vaccine AdC7-M/E Protects against Zika Virus Infection and Testis Damage.
    Xu K; Song Y; Dai L; Zhang Y; Lu X; Xie Y; Zhang H; Cheng T; Wang Q; Huang Q; Bi Y; Liu WJ; Liu W; Li X; Qin C; Shi Y; Yan J; Zhou D; Gao GF
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29298885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope.
    Long F; Doyle M; Fernandez E; Miller AS; Klose T; Sevvana M; Bryan A; Davidson E; Doranz BJ; Kuhn RJ; Diamond MS; Crowe JE; Rossmann MG
    Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1591-1596. PubMed ID: 30642974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralization of Zika virus by E protein domain III-Specific human monoclonal antibody.
    Kim SI; Kim S; Shim JM; Lee HJ; Chang SY; Park S; Min JY; Park WB; Oh MD; Kim S; Chung J
    Biochem Biophys Res Commun; 2021 Mar; 545():33-39. PubMed ID: 33535104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the immunogenicity of Zika glycan loop.
    Henderson EA; Tam CC; Cheng LW; Ngono AE; Nguyen AV; Shresta S; McGee M; Padgett H; Grill LK; Martchenko Shilman M
    Virol J; 2020 Mar; 17(1):43. PubMed ID: 32234060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and characterization of mouse monoclonal antibodies targeting to distinct epitopes of Zika virus envelope protein for specific detection of Zika virus.
    Li CJ; Huang PH; Chen HW; Chang SC
    Appl Microbiol Biotechnol; 2021 Jun; 105(11):4663-4673. PubMed ID: 34043078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probing Zika Virus Neutralization Determinants with Glycoprotein Mutants Bearing Linear Epitope Insertions.
    Chambers MT; Schwarz MC; Sourisseau M; Gray ES; Evans MJ
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structures of the Zika Virus Envelope Protein and Its Complex with a Flavivirus Broadly Protective Antibody.
    Dai L; Song J; Lu X; Deng YQ; Musyoki AM; Cheng H; Zhang Y; Yuan Y; Song H; Haywood J; Xiao H; Yan J; Shi Y; Qin CF; Qi J; Gao GF
    Cell Host Microbe; 2016 May; 19(5):696-704. PubMed ID: 27158114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large-scale analysis of B-cell epitopes of envelope: Implications for Zika vaccine and immunotherapeutic development.
    Almansour I; Alfares R; Aljofi H
    F1000Res; 2018; 7():1624. PubMed ID: 31316749
    [No Abstract]   [Full Text] [Related]  

  • 16. Structural Basis of Zika Virus-Specific Antibody Protection.
    Zhao H; Fernandez E; Dowd KA; Speer SD; Platt DJ; Gorman MJ; Govero J; Nelson CA; Pierson TC; Diamond MS; Fremont DH
    Cell; 2016 Aug; 166(4):1016-1027. PubMed ID: 27475895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human antibody response to Zika targets type-specific quaternary structure epitopes.
    Collins MH; Tu HA; Gimblet-Ochieng C; Liou GA; Jadi RS; Metz SW; Thomas A; McElvany BD; Davidson E; Doranz BJ; Reyes Y; Bowman NM; Becker-Dreps S; Bucardo F; Lazear HM; Diehl SA; de Silva AM
    JCI Insight; 2019 Apr; 4(8):. PubMed ID: 30996133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Zika virus binding and enhancement potential of a large panel of flavivirus murine monoclonal antibodies.
    Willis E; Hensley SE
    Virology; 2017 Aug; 508():1-6. PubMed ID: 28475924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody.
    Esswein SR; Gristick HB; Jurado A; Peace A; Keeffe JR; Lee YE; Voll AV; Saeed M; Nussenzweig MC; Rice CM; Robbiani DF; MacDonald MR; Bjorkman PJ
    Proc Natl Acad Sci U S A; 2020 May; 117(18):9865-9875. PubMed ID: 32321830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus.
    Dejnirattisai W; Supasa P; Wongwiwat W; Rouvinski A; Barba-Spaeth G; Duangchinda T; Sakuntabhai A; Cao-Lormeau VM; Malasit P; Rey FA; Mongkolsapaya J; Screaton GR
    Nat Immunol; 2016 Sep; 17(9):1102-8. PubMed ID: 27339099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.